INTEGER HOLDINGS CORPORATION Accounts Receivable, Sale
INTEGER HOLDINGS CORPORATION (ITGR) reported Accounts Receivable, Sale of $25.10 million for the 6-month period ending 2026-07-03, per its 10-Q filed 2026-08-04.
Financial Statements › Notes
us-gaap:AccountsReceivableSale · last filed 2026-08-04
- INTEGER HOLDINGS CORPORATION accounts receivable, sale for the quarter ending 2026-07-03 was $15.00M, a 79.45% decline year-over-year.
- INTEGER HOLDINGS CORPORATION accounts receivable, sale for the quarter ending 2026-04-03 was $10.10M, a 82.62% decline year-over-year.
- INTEGER HOLDINGS CORPORATION accounts receivable, sale for the quarter ending 2025-12-31 was $26.90M, a 60.67% decline year-over-year.
- INTEGER HOLDINGS CORPORATION accounts receivable, sale for the quarter ending 2025-09-26 was $70.70M, a 54.37% increase year-over-year.
- INTEGER HOLDINGS CORPORATION accounts receivable, sale for fiscal 2025 was $228.70M, a 1.00% decline from fiscal 2024.
- INTEGER HOLDINGS CORPORATION accounts receivable, sale for fiscal 2024 was $231.00M, a 59.97% increase from fiscal 2023.
- INTEGER HOLDINGS CORPORATION accounts receivable, sale for fiscal 2023 was $144.40M, a 19.64% increase from fiscal 2022.
- INTEGER HOLDINGS CORPORATION accounts receivable, sale for fiscal 2022 was $120.70M, a 3.96% increase from fiscal 2021.
| Period end | Accounts Receivable, Sale 3 month | Accounts Receivable, Sale 6 month | Accounts Receivable, Sale 9 month | Accounts Receivable, Sale 12 month |
|---|---|---|---|---|
| 2026-07-03 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $25.10M 10-Q · filed 2026-08-04 | $52.00M derived: sum of 3 quarters · filed 2026-08-04 | $122.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-04-03 | $10.10M 10-Q · filed 2026-04-30 | $37.00M derived: sum of 2 quarters · filed 2026-04-30 | $107.70M derived: sum of 3 quarters · filed 2026-04-30 | $180.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $26.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $97.60M derived: sum of 2 quarters · filed 2026-02-23 | $170.60M derived: sum of 3 quarters · filed 2026-08-04 | $228.70M 10-K · filed 2026-02-23 |
| 2025-09-26 | $70.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $143.70M derived: sum of 2 quarters · filed 2026-08-04 | $201.80M 10-Q · filed 2025-10-23 | $270.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-27 | $73.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $131.10M 10-Q · filed 2026-08-04 | $199.50M derived: sum of 3 quarters · filed 2026-08-04 | $245.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-28 | $58.10M 10-Q · filed 2026-04-30 | $126.50M derived: sum of 2 quarters · filed 2026-04-30 | $172.30M derived: sum of 3 quarters · filed 2026-04-30 | $231.50M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $68.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $114.20M derived: sum of 2 quarters · filed 2026-02-23 | $173.40M derived: sum of 3 quarters · filed 2026-02-23 | $231.00M 10-K · filed 2026-02-23 |
| 2024-09-27 | $45.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $105.00M derived: sum of 2 quarters · filed 2025-10-23 | $162.60M 10-Q · filed 2025-10-23 | $209.60M derived: sum of 4 quarters · filed 2025-10-23 |
| 2024-06-28 | $59.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-24 | $116.80M 10-Q · filed 2025-07-24 | $163.80M derived: sum of 3 quarters · filed 2025-07-24 | $210.90M derived: sum of 4 quarters · filed 2025-07-24 |
| 2024-03-29 | $57.60M 10-Q · filed 2025-04-24 | $104.60M derived: sum of 2 quarters · filed 2025-04-24 | $151.70M derived: sum of 3 quarters · filed 2025-04-24 | |
| 2023-12-31 | $47.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $94.10M derived: sum of 2 quarters · filed 2025-02-20 | $144.40M 10-K · filed 2025-02-20 | |
| 2023-09-29 | $47.10M 10-Q · filed 2023-10-26 | $97.40M 10-Q · filed 2024-10-24 | ||
| 2023-06-30 | $50.30M 10-Q · filed 2024-07-25 | |||
| 2022-12-31 | $120.70M 10-K · filed 2023-02-21 | |||
| 2021-12-31 | $116.10M 10-K · filed 2023-02-21 | |||
| 2020-12-31 | $26.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22 | $42.40M derived: sum of 2 quarters · filed 2022-02-22 | $57.80M derived: sum of 3 quarters · filed 2022-02-22 | $73.30M 10-K · filed 2022-02-22 |
| 2020-10-02 | $16.20M 10-Q · filed 2020-10-29 | $31.60M derived: sum of 2 quarters · filed 2020-10-29 | $47.10M 10-Q · filed 2020-10-29 | |
| 2020-07-03 | $15.40M 10-Q · filed 2020-07-30 | $30.90M 10-Q · filed 2020-07-30 | ||
| 2020-04-03 | $15.50M 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LivaNova PLC (LIVN) | $4.158B | 24.01 | |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |